Originally formed in St. Louis, MO with exclusive technology licensed from Washington University. InvivoSciences, LLC creates, manufactures and markets tools for three dimensional (3D) cell culture systems and provides compound screening services with them. InvivoSciences, Inc. (IVS) is now organized around developing technologies to mass-produce micro engineered tissues and their high-throughput (HTP) phenotype analyzer for drug discovery screening. Prior to human trials, the HTP analyzer supports predicting efficacy, safety, and dose of drug candidates. The firm's lead product, 3D engineered heart tissues (EHTs) can beat for more than 6 months in dishes, making it an ideal choice for identifying cardio-active and cardio-toxic compounds for acute and chronic studies. Using the induced pluripotent stem cell (iPSC) technology, the firm's 3D tissue models recapitulate physiological properties of functional heart tissues in healthy and diseased states in patients. This enables developers to discover personalized treatments in genetic disorders, while physicians can prioritize therapeutic options. The 3D engineered tissue technology has been applied to various tissue types, including smooth and skeletal muscle, connective tissue, as well as 3D cancer models. IVS is currently focusing on capturing the market applying the EHT-based screening platform in academic research, drug discovery, and environmental toxicology. Multiple grants and contracts from National Institutes of Health has enabled the firm to integrate cell and tissue engineering, assay automation, computational biologists and medicinal chemistry. InvivoSciences is ready to offer rapid and cost-effective platforms for unprecedented preclinical discovery of therapeutics for the right patient population using patient-specific EHTs. IVS utilizes this unique system to offer contract research services in drug cardiac safety analyses and drug-target analysis for general and inherited cardiac disorders, which is still a significant unmet need.
